Cargando…

Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location

Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2 genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline BRCA1 to BRCA2 mutations in BRCA-related cancer patients vary depending on the population. Genotype and phenotype correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, Masayuki, Nishino, Koji, Enomoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303997/
https://www.ncbi.nlm.nih.gov/pubmed/34356066
http://dx.doi.org/10.3390/genes12071050
_version_ 1783727226290700288
author Sekine, Masayuki
Nishino, Koji
Enomoto, Takayuki
author_facet Sekine, Masayuki
Nishino, Koji
Enomoto, Takayuki
author_sort Sekine, Masayuki
collection PubMed
description Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2 genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline BRCA1 to BRCA2 mutations in BRCA-related cancer patients vary depending on the population. Genotype and phenotype correlations have been reported in BRCA mutant families, however, the correlations are rarely used for individual risk assessment and management. BRCA genetic testing has become a companion diagnostic for PARP inhibitors, and the number of families with germline BRCA mutation identified is growing rapidly. Therefore, it is expected that analysis of the risk of developing cancer will be possible in a large number of BRCA mutant carriers, and there is a possibility that personal and precision medicine for the carriers with specific common founder mutations will be realized. In this review, we investigated the association of ovarian cancer risk and BRCA mutation location, and differences of other BRCA-related cancer risks by BRCA1/2 mutation, and furthermore, we discussed the difference in the prevalence of germline BRCA mutation in ovarian cancer patients. As a result, although there are various discussions, there appear to be differences in ovarian cancer risk by population and BRCA mutation location. If it becomes possible to estimate the risk of developing BRCA-related cancer for each BRCA mutation type, the age at risk-reducing salpingo-oophorectomy can be determined individually. The decision would bring great benefits to young women with germline BRCA mutations.
format Online
Article
Text
id pubmed-8303997
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83039972021-07-25 Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location Sekine, Masayuki Nishino, Koji Enomoto, Takayuki Genes (Basel) Review Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2 genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline BRCA1 to BRCA2 mutations in BRCA-related cancer patients vary depending on the population. Genotype and phenotype correlations have been reported in BRCA mutant families, however, the correlations are rarely used for individual risk assessment and management. BRCA genetic testing has become a companion diagnostic for PARP inhibitors, and the number of families with germline BRCA mutation identified is growing rapidly. Therefore, it is expected that analysis of the risk of developing cancer will be possible in a large number of BRCA mutant carriers, and there is a possibility that personal and precision medicine for the carriers with specific common founder mutations will be realized. In this review, we investigated the association of ovarian cancer risk and BRCA mutation location, and differences of other BRCA-related cancer risks by BRCA1/2 mutation, and furthermore, we discussed the difference in the prevalence of germline BRCA mutation in ovarian cancer patients. As a result, although there are various discussions, there appear to be differences in ovarian cancer risk by population and BRCA mutation location. If it becomes possible to estimate the risk of developing BRCA-related cancer for each BRCA mutation type, the age at risk-reducing salpingo-oophorectomy can be determined individually. The decision would bring great benefits to young women with germline BRCA mutations. MDPI 2021-07-08 /pmc/articles/PMC8303997/ /pubmed/34356066 http://dx.doi.org/10.3390/genes12071050 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sekine, Masayuki
Nishino, Koji
Enomoto, Takayuki
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title_full Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title_fullStr Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title_full_unstemmed Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title_short Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
title_sort differences in ovarian and other cancers risks by population and brca mutation location
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303997/
https://www.ncbi.nlm.nih.gov/pubmed/34356066
http://dx.doi.org/10.3390/genes12071050
work_keys_str_mv AT sekinemasayuki differencesinovarianandothercancersrisksbypopulationandbrcamutationlocation
AT nishinokoji differencesinovarianandothercancersrisksbypopulationandbrcamutationlocation
AT enomototakayuki differencesinovarianandothercancersrisksbypopulationandbrcamutationlocation